Skip to main content
Top
Published in: International Journal of Hematology 4/2009

01-11-2009 | Original Article

Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems

Authors: Shinsaku Imashuku, Naoko Kinugawa, Akinobu Matsuzaki, Toshiyuki Kitoh, Kentaro Ohki, Yoko Shioda, Yukiko Tsunematsu, Toshihiko Imamura, Akira Morimoto, Japan LCH Study Group

Published in: International Journal of Hematology | Issue 4/2009

Login to get access

Abstract

Langerhans cell histiocytosis (LCH) can be a single system or multi-system disease. Both disease types can be associated with multi-focal bone lesions, but their bone involvement patterns have not been compared systematically. Of the new pediatric LCH cases enrolled into the JLSG-02 study during 2002–2007, 67 cases of single system multifocal bone (SMFB) LCH and 97 cases of multi-system bone (MSB) LCH were analyzed to determine if the bone involvement patterns differ in these two types, and whether these differences correlate with outcome. Statistical analysis was performed with Mann–Whitney U test, Fisher’s exact test, and other measures. Onset ages were higher for SMFB (P < 0.001), but the two types did not differ in the number of bone lesions per patient. The skull was most frequently affected in both types, followed by the spine. Lesions in the temporal bone (P = 0.002), ear-petrous bone (P < 0.001), orbita (P = 0.003), and zygomatic bone (P = 0.016) were significantly more common in MSB. The two types did not differ in response to treatment, but MSB was associated with a significantly higher incidence of diabetes insipidus (DI) (P < 0.001). Novel measures are required in preventing the development of DI in MSB-type LCH patients with “risk” bone lesions.
Literature
1.
go back to reference Weitzman S, Egeler RM. Langerhans cell histiocytosis of bone. In: Weitzman S, Egeler RM, editors. Histiocytic disorders of children and adults; basic science, clinical features and therapy. UK: Cambridge University Press; 2005. p. 154–73.CrossRef Weitzman S, Egeler RM. Langerhans cell histiocytosis of bone. In: Weitzman S, Egeler RM, editors. Histiocytic disorders of children and adults; basic science, clinical features and therapy. UK: Cambridge University Press; 2005. p. 154–73.CrossRef
2.
go back to reference Stuurman KE, Lau I, Doda W, et al. The natural history and long term complications of patients with Langerhans cell histiocytosis of bone. In: Proceedings of XIX meeting Histocyte Society, Philadelphia 2003, pp 55. Stuurman KE, Lau I, Doda W, et al. The natural history and long term complications of patients with Langerhans cell histiocytosis of bone. In: Proceedings of XIX meeting Histocyte Society, Philadelphia 2003, pp 55.
3.
go back to reference Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37:108–14.CrossRefPubMed Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37:108–14.CrossRefPubMed
5.
go back to reference Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC, Unni KK. Langerhans’ cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995;76:2471–84.CrossRefPubMed Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC, Unni KK. Langerhans’ cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995;76:2471–84.CrossRefPubMed
6.
go back to reference Ghanem I, Tolo VT, D’Ambra P, Malogalowkin MH. Langerhans cell histiocytosis of bone in children and adolescents. J Pediatr Orthop. 2003;23:124–30.PubMed Ghanem I, Tolo VT, D’Ambra P, Malogalowkin MH. Langerhans cell histiocytosis of bone in children and adolescents. J Pediatr Orthop. 2003;23:124–30.PubMed
7.
go back to reference Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107:613–9.CrossRefPubMed Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107:613–9.CrossRefPubMed
8.
go back to reference Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46:228–33.CrossRefPubMed Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46:228–33.CrossRefPubMed
9.
go back to reference Imashuku S, Shioda Y, Kobayashi R, et al. Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group. Haematologica. 2008;93:615–8.CrossRefPubMed Imashuku S, Shioda Y, Kobayashi R, et al. Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group. Haematologica. 2008;93:615–8.CrossRefPubMed
10.
go back to reference Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14:2073–82.CrossRefPubMed Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14:2073–82.CrossRefPubMed
11.
go back to reference Davidson L, McComb JG, Bowen I, Krieger MD. Craniospinal Langerhans cell histiocytosis in children: 30 years’ experience at a single institution. J Neurosurg Pediatrics. 2008;1:187–95.CrossRef Davidson L, McComb JG, Bowen I, Krieger MD. Craniospinal Langerhans cell histiocytosis in children: 30 years’ experience at a single institution. J Neurosurg Pediatrics. 2008;1:187–95.CrossRef
12.
go back to reference Nebelung W, Röpke M, Kluba U, Aumann V, Radig K, Mittler U. Treatment concepts in bone manifestations of Langerhans cell histiocytosis. Z Orthop Ihre Grenzgeb. 1999;137:236–43. [in German].CrossRefPubMed Nebelung W, Röpke M, Kluba U, Aumann V, Radig K, Mittler U. Treatment concepts in bone manifestations of Langerhans cell histiocytosis. Z Orthop Ihre Grenzgeb. 1999;137:236–43. [in German].CrossRefPubMed
13.
go back to reference Jubran RF, Marachelian A, Dorey F, et al. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005;45:37–42.CrossRefPubMed Jubran RF, Marachelian A, Dorey F, et al. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005;45:37–42.CrossRefPubMed
14.
go back to reference Stull MA, Kransdorf MJ, Devaney KO. Langerhans cell histiocytosis of bone. Radiographics. 1992;12:801–23.CrossRefPubMed Stull MA, Kransdorf MJ, Devaney KO. Langerhans cell histiocytosis of bone. Radiographics. 1992;12:801–23.CrossRefPubMed
15.
go back to reference Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28:9–14.CrossRefPubMed Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28:9–14.CrossRefPubMed
16.
go back to reference Wester SM, Beabout JW, Unni KK, Dahlin DC. Langerhans’ cell granulomatosis (histiocytosis X) of bone in adults. Am J Surg Pathol. 1982;6:413–26.CrossRefPubMed Wester SM, Beabout JW, Unni KK, Dahlin DC. Langerhans’ cell granulomatosis (histiocytosis X) of bone in adults. Am J Surg Pathol. 1982;6:413–26.CrossRefPubMed
17.
go back to reference Garg S, Mehta S, Dormans JP. Langerhans cell histiocytosis of the spine in children. Long-term follow-up. J Bone Joint Surg Am. 2004;86-A:1740–50.CrossRefPubMed Garg S, Mehta S, Dormans JP. Langerhans cell histiocytosis of the spine in children. Long-term follow-up. J Bone Joint Surg Am. 2004;86-A:1740–50.CrossRefPubMed
18.
go back to reference Morimoto A, Kobayashi R, Maeda M, Asami K, Bessho F, Imashuku S, et al. Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients. Pediatr Blood Cancer. 2008;50:931–2.CrossRefPubMed Morimoto A, Kobayashi R, Maeda M, Asami K, Bessho F, Imashuku S, et al. Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients. Pediatr Blood Cancer. 2008;50:931–2.CrossRefPubMed
19.
go back to reference Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42:438–44.CrossRefPubMed Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42:438–44.CrossRefPubMed
20.
go back to reference Grois N, Prayer D, Prosch H, et al. Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:59–65.CrossRefPubMed Grois N, Prayer D, Prosch H, et al. Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:59–65.CrossRefPubMed
21.
go back to reference Minkov M, Grois N, Braier J, et al. Immunosuppressive treatment for chemotherapy-resistant multisystem Langerhans cell histiocytosis. Med Pediatr Oncol. 2003;40:253–6.CrossRefPubMed Minkov M, Grois N, Braier J, et al. Immunosuppressive treatment for chemotherapy-resistant multisystem Langerhans cell histiocytosis. Med Pediatr Oncol. 2003;40:253–6.CrossRefPubMed
Metadata
Title
Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems
Authors
Shinsaku Imashuku
Naoko Kinugawa
Akinobu Matsuzaki
Toshiyuki Kitoh
Kentaro Ohki
Yoko Shioda
Yukiko Tsunematsu
Toshihiko Imamura
Akira Morimoto
Japan LCH Study Group
Publication date
01-11-2009
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0420-4

Other articles of this Issue 4/2009

International Journal of Hematology 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine